Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
Abbott Park, Illinois, (NYSE: ABT) — A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott’s ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If ...